Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) recently released a strong earnings report, and the market responded ...

As the U.S. market experiences a mix of record highs and tempered expectations due to recent inflation reports, investors are closely monitoring economic indicators that could influence Federal ...

ACADIA Pharmaceuticals (NASDAQ: ACAD) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates ...

ACADIA Pharmaceuticals shares are trading lower by 4.11% during Tuesday's session. The company appointed Catherine Owen Adams as CEO. The next correction is closer than you think. Find out how Tom ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed ...

Acadia Pharmaceuticals strengthens Nuplazid's IP, anticipates stabilization in commercial performance, and eyes future pipeline value. Read more on how ACAD stock is a Buy.

We have a conviction buy rating on Acadia Pharmaceuticals' common stock (price target of $47.57 based on sum-of-the parts DCF method). The company is also an attractive acquisition target.

Acadia Pharmaceuticals (ACAD 14.48%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.